Jubilant Generics Company Profile
What is the competitive landscape for JUBILANT GENERICS
JUBILANT GENERICS has fifty approved drugs.
Summary for Jubilant Generics
| US Patents: | 0 |
| Tradenames: | 44 |
| Ingredients: | 43 |
| NDAs: | 50 |
Drugs and US Patents for Jubilant Generics
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jubilant Generics | SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 205484-002 | Oct 2, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Jubilant Generics | AMANTADINE HYDROCHLORIDE | amantadine hydrochloride | TABLET;ORAL | 210403-001 | Feb 7, 2018 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Jubilant Generics | ZOLMITRIPTAN | zolmitriptan | TABLET, ORALLY DISINTEGRATING;ORAL | 202956-002 | Sep 17, 2015 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| Jubilant Generics | SOLIFENACIN SUCCINATE | solifenacin succinate | TABLET;ORAL | 205484-001 | Oct 2, 2024 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
